Because of its chemical versatility and demonstrated biocom-sion between the cells and the polymer surface. Cell adhesion patibility, poly(2-hydroxyethyl methacrylate) (pHEMA) has was weaker on pHEMA, as a significant fraction of the fibrobeen widely used as a polymer for biomedical applications. b
Biotransformation enzymes and lung cell response to 2-hydroxyethyl-methacrylate
✍ Scribed by J. T. Samuelsen; J. A. Holme; M. Låg; P. E. Schwarze; J. E. Dahl; R. Becher
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 455 KB
- Volume
- 100A
- Category
- Article
- ISSN
- 1549-3296
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The aim of this in vitro study was to investigate possible involvement of cytochrome P450 (CYP) enzymes in modifying the toxic potential of 2‐hydroxyethyl‐methacrylate (HEMA). Primary cultures of CYP expressing rat alveolar type 2 cells were exposed to varying concentrations of HEMA. Nuclear translocation of aryl hydrocarbon receptor (AhR) after HEMA exposure (100 μ__M__) was demonstrated by immunocytochemical staining. Using reverse transcriptase PCR, increased mRNA level of AhR‐regulated genes encoding enzymes associated with detoxification of xenobiotics were found. Exposure to 1 m__M__ HEMA rapidly (6 h) resulted in cells with an apoptotic like morphology as suggested by marked nuclear condensation. Cotreatment of the HEMA exposed cells with a CYP inhibitor (disulfiram) or an antioxidant (vitamin C) effectively rescued the cells from this fate. Despite this effect of vitamin C, no increased level of reactive oxygen species was observed in the HEMA exposed cells. Our results suggest that HEMA activates AhR regulated gene transcription and that CYP is involved in the formation of a highly reactive HEMA metabolite. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2012.
📜 SIMILAR VOLUMES
Hydrogels of poly(hydroxyethy1 methacrylate) (polyHEMA) homopolymer do not normally support the attachment and growth of mammalian cells. By altering the surface it has been possible to dramatically change this cell-substratum interaction so that vascular endothelial cells can attach and completely
## Abstract ## BACKGROUND. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC), particularly those with tumors that have EGFR‐TK domain mutations. Moreover, the EGFR and cyclooxygenase (COX)‐2